Lion Point Capital, LP Fennec Pharmaceuticals Inc. Transaction History
Lion Point Capital, LP
- $37.2 Million
- Q3 2024
A detailed history of Lion Point Capital, LP transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Lion Point Capital, LP holds 215,000 shares of FENC stock, worth $1.14 Million. This represents 2.89% of its overall portfolio holdings.
Number of Shares
215,000
Previous 170,000
26.47%
Holding current value
$1.14 Million
Previous $1.04 Million
3.56%
% of portfolio
2.89%
Previous 2.22%
Shares
3 transactions
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.9MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$21.7 Million0.57% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$12.8 Million27.51% of portfolio
-
Solas Capital Management, LLC Darien, CT1.92MShares$10.2 Million7.68% of portfolio
-
Dg Capital Management, LLC New York, NY1.52MShares$8.1 Million4.41% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$6.32 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $139M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...